Gross Profit Analysis: Comparing Eli Lilly and Company and Ligand Pharmaceuticals Incorporated

Eli Lilly vs. Ligand: A Decade of Profit Growth

__timestampEli Lilly and CompanyLigand Pharmaceuticals Incorporated
Wednesday, January 1, 20141468310000055402000
Thursday, January 1, 20151492150000066107000
Friday, January 1, 201615567200000103402000
Sunday, January 1, 201716801100000135736000
Monday, January 1, 201816811600000245116000
Tuesday, January 1, 201917598300000108935000
Wednesday, January 1, 202019056500000156000000
Friday, January 1, 202121005600000214957000
Saturday, January 1, 202221911600000143418000
Sunday, January 1, 20232704190000096265000
Monday, January 1, 202436624400001
Loading chart...

Unleashing insights

Gross Profit Trends: Eli Lilly vs. Ligand Pharmaceuticals

In the ever-evolving pharmaceutical industry, understanding financial performance is crucial. This analysis compares the gross profit trends of Eli Lilly and Company and Ligand Pharmaceuticals Incorporated from 2014 to 2023. Eli Lilly, a giant in the pharmaceutical world, has shown a robust growth trajectory, with its gross profit increasing by approximately 84% over the decade. In contrast, Ligand Pharmaceuticals, a smaller player, experienced a more modest growth of around 74% during the same period.

Key Insights

  • Eli Lilly's Dominance: By 2023, Eli Lilly's gross profit reached nearly 27 billion, showcasing its strong market position.
  • Ligand's Growth: Despite its smaller scale, Ligand's gross profit peaked in 2018, highlighting its potential in niche markets.

These insights underscore the dynamic nature of the pharmaceutical sector, where both giants and smaller firms can thrive.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025